CLL/SLL

Should we treat newly diagnosed patients with CLL differently after ASH 2019?

L: English

During the 61st American Society of Hematology (ASH) meeting in Orlando, US, the Lymphoma Hub was pleased to speak to Astrid Pavlovsky, Fundaleu CHP, Buenos Aires, AR. We asked: Should we treat newly diagnosed patients with chronic lymphocytic leukemia differently after ASH 2019?

Astrid Pavlovsky talks about the importance of genetic characterization of CLL to guide patient treatment pathway. She also discusses the results of the ELEVATE trial, that examines a new treatment option for elderly patients with CLL.